Clinical Trial Update: A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer [Phase 2]

View source ↗

Summary

A Phase II study evaluating cetuximab and bevacizumab in recurrent or metastatic head and neck squamous cell carcinoma has completed, with results posted in Jul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Avastin (bevacizumab)
• ERBITUX (cetuximab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Head and Neck Cancer, Squamous Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2016-07-12